ConductScience.org, home
Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia
API referenceFor AI assistants

Trial · NCT03176771

Participant flow30

How many started, completed or left each group, period by period.

1 to 20 of 30

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Double-Blind Placebo-Controlled PeriodSTARTEDPlacebo (Double-Blind Placebo-Controlled Period)85
Double-Blind Placebo-Controlled PeriodSTARTEDMT-5199 40 mg (Double-Blind Placebo-Controlled Period)86
Double-Blind Placebo-Controlled PeriodSTARTEDMT-5199 80 mg (Double-Blind Placebo-Controlled Period)85
Double-Blind Placebo-Controlled PeriodSTARTEDMT-5199 40 mg (Double-Blind Extension Period)0
Double-Blind Placebo-Controlled PeriodSTARTEDMT-5199 80 mg (Double-Blind Extension Period)0
Double-Blind Placebo-Controlled PeriodCOMPLETEDPlacebo (Double-Blind Placebo-Controlled Period)80
Double-Blind Placebo-Controlled PeriodCOMPLETEDMT-5199 40 mg (Double-Blind Placebo-Controlled Period)71
Double-Blind Placebo-Controlled PeriodCOMPLETEDMT-5199 80 mg (Double-Blind Placebo-Controlled Period)60
Double-Blind Placebo-Controlled PeriodCOMPLETEDMT-5199 40 mg (Double-Blind Extension Period)0
Double-Blind Placebo-Controlled PeriodCOMPLETEDMT-5199 80 mg (Double-Blind Extension Period)0
Double-Blind Placebo-Controlled PeriodNOT COMPLETEDPlacebo (Double-Blind Placebo-Controlled Period)5
Double-Blind Placebo-Controlled PeriodNOT COMPLETEDMT-5199 40 mg (Double-Blind Placebo-Controlled Period)15
Double-Blind Placebo-Controlled PeriodNOT COMPLETEDMT-5199 80 mg (Double-Blind Placebo-Controlled Period)25
Double-Blind Placebo-Controlled PeriodNOT COMPLETEDMT-5199 40 mg (Double-Blind Extension Period)0
Double-Blind Placebo-Controlled PeriodNOT COMPLETEDMT-5199 80 mg (Double-Blind Extension Period)0
Double-Blind Extension PeriodSTARTEDPlacebo (Double-Blind Placebo-Controlled Period)0
Double-Blind Extension PeriodSTARTEDMT-5199 40 mg (Double-Blind Placebo-Controlled Period)0
Double-Blind Extension PeriodSTARTEDMT-5199 80 mg (Double-Blind Placebo-Controlled Period)0
Double-Blind Extension PeriodSTARTEDMT-5199 40 mg (Double-Blind Extension Period)112
Double-Blind Extension PeriodSTARTEDMT-5199 80 mg (Double-Blind Extension Period)99

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03176771/flow

API referenceFor AI assistants